TrialNature medicine2024

The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.

Lindsay B Kilburn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.